方法：于2012-01/2013-08选取门诊非增生性糖尿病视网膜患者68例，按照随机数字表将患者均分为对照组及观察组，对照组常规药物降糖治疗，观察组在对照组的基础上予普罗布考(0.375g，每日2次)，平均随访11.58±0.17mo。同时征集基线情况相匹配的健康志愿者16例为正常对照组。观察治疗前后两组患者空腹血糖，餐后血糖，糖化血红蛋白，糖尿病视网膜病变分期的进展率及缓解率以及氧化应激相关指标总抗氧化能力(TAOC)、超氧化物歧化酶(SOD)、丙二醛(MDA)变化。

结果：两组患者治疗前后空腹血糖，餐后血糖，糖化血红蛋白均无明显变化，差异无统计学意义。对照组患者治疗后糖尿病视网膜病变分期缓解率及进展率分别为3%及19%，而观察组患者经普罗布考治疗，糖尿病视网膜病变分期缓解率及进展率分别为18%及5%，与对照组相比，差异有统计学意义(P<0.05)。对照组治疗前后TAOC，SOD，MDA无明显变化，观察组治疗后TAOC，SOD明显增高，MDA显著降低(P<0.05)，较对照组患者治疗后变化有统计学意义(P<0.05)。

结论：普罗布考能改善非增生性糖尿病视网膜病变患者的抗氧化应激状态，提高糖尿病视网膜病变患者的治疗效果。

METHODS:Sixty-eight clinic patients with nonproliferative diabetic retinopathy were selected from January, 2012 to August, 2013. According to the random number table, the patients were divided into control group and observation group, the control group was received conventional medicine for hypoglycemic therapy, and the observation group was given probucol(0.375g, twice daily)on the basis of control group. All patients were followed up for average 11.58±0.17mo. At the same time 16 healthy volunteers matched with baseline were collected as normal control group. Changes in fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, the staging progress rate and the remission rate of diabetic retinopathy, and indicators related to oxidative stress, such as, total antioxide capacity(TAOC), superoxide dismutase(SOD), and methane dicarboxy aldehyde(MDA), of two groups of patients before and after therapy were observed.

RESULTS: Fasting blood glucose,postprandial blood glucose, and glycosylated hemoglobin of patients in two groups before and after therapy showed no significant changes, and the differences had no statistical significance. The staging remission rate and the progress rate of diabetic retinopathy of the control group after therapy were 3% and 19% respectively. The staging remission rate and the progress rate of diabetic retinopathy of the observation group after probucol therapy were 18% and 5% respectively. In comparison with the control group, the difference had statistical significance(P<0.05). TAOC, SOD, MDA of the control group before and after therapy had no obvious change, but TAOC, SOD of the observation group after therapy had significantly increased, and MDA had significantly decreased(P<0.05), with statistical significance in comparison with the changes of the patients in the control group after therapy(P<0.05).

CONCLUSION:Probucol can improve the antioxidative stress status of the patients with nonproliferative diabetic retinopathy, and enhance the therapeutic effect of the patients with diabetic retinopathy.